Objective: To analyze the transformation of diagnostic and therapeutic paradigms in the management of vertigo and vestibular disorders, evaluating recent evidence on emergency clinical algorithms, pharmacological safety in vulnerable populations, and the emergence of precision medicine in inner ear pathologies. Method: A systematic literature review was conducted following PRISMA methodology. Biomedical databases (PubMed, Cochrane Library, Embase) and clinical trial registries were consulted to identify studies published between January 2020 and February 2025. Meta-analyses, randomized controlled trials, and clinical practice guidelines (Bárány Society, ACORL, IETS) were included. Results: Current evidence dismisses diagnosis based on symptom quality ("vertigo" vs. "dizziness") in favor of the TiTrATE model (Timing, Triggers, And Targeted Examination). HINTS+ and STANDING physical examination protocols demonstrate superior sensitivity to diffusion-weighted magnetic resonance imaging (DWI) in the first 48 hours of acute vestibular syndrome (AVS). In pharmacology, the 2024 Beers Criteria severely restrict the use of vestibular antihistamines in geriatrics, while droperidol re-emerges as a safe antiemetic standard at low doses. In Menière's Disease, the identification of immunological phenotypes and rare genetic variants paves the way for targeted therapies such as Ebselen (SPI-1005). Regarding vestibular neuritis, recent meta-analyses (2024-2025) confirm the inefficacy of corticosteroids for long-term functional recovery. Conclusions: Neuro-otology is transitioning towards a stage of diagnostic precision where instrumented oculomotor semiology and molecular biomarkers displace indiscriminate imaging and empirical vestibular suppression. Urgent updating of hospital protocols is required to integrate these findings and minimize iatrogenesis in at-risk populations.
1 January 2026 in Neurology Research International
Background: Progressive supranuclear palsy (PSP) is a rare 4‐repeat tauopathy characterized by marked clinical heterogeneity and frequent diagnostic delay. Epidemiological and phenotypic data from Latin America remain limited. This study aimed to describe the clinical and epidemiological characteristics of PSP in a Colombian referral center and to compare findings by sex and phenotype. Methods: We retrospectively reviewed PSP cases evaluated at a Colombian neurological referral center from 2013 to 2023. Demographic, clinical, neuroimaging, diagnostic, and treatment‐related variables were extracted from medical records. PSP phenotypes were retrospectively classified and grouped using clinical information from medical records. Period prevalence was estimated using the adult population of Antioquia as the denominator. Results: Among 152 patients, 53.9% were male. Crude period prevalence was 1.8 per 100,000 adults, peaking at 75–84 years. Women were older than men at evaluation, whereas age at symptom onset was similar between sexes. Mean diagnostic delay was approximately 3.5 years. Postural instability was the most frequent presenting symptom. PSP‐Richardson syndrome and PSP‐parkinsonism were the most common phenotypes. MRI was the most frequently requested imaging study, and midbrain atrophy was the most common abnormality. Levodopa/carbidopa was the most frequently prescribed medication, with documented initial response in only a subset of treated patients. Conclusions: PSP in this Colombian cohort predominantly affected older adults and was characterized by substantial diagnostic delay, marked phenotypic heterogeneity, and predominantly symptomatic treatment. These findings expand the limited Latin American literature and underscore the need for earlier recognition of both typical and atypical PSP presentations.